Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Lung diseases

Lung diseases

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Lung diseases

27 trials tracked for Lung diseases: 9 in phase 3 or 4 and 3 with published results. The most-cited published study has 428 citations.

27Trials tracked
9Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 3 Phase 3 6 Phase 2 7 Phase 1 3 Other / NA 8
  1. Phase 3 Apnea Positive Pressure Long-Term Efficacy Study Completed · 428 cited
  2. Phase 3 Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008) Completed · 149 cited
  3. Phase 4 Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS) Completed · 130 cited
  4. Phase 4 Individualizing Treatment for Asthma in Primary Care Completed
  5. Phase 4 Efficacy of Intercostal CryoAnalgesia in Robotic Lung Resection Completed
  6. Phase 3 Montelukast for Early Life Wheezing Completed
Show 21 more trials
  1. Phase 3 Childhood Asthma Management Program (CAMP) Phases I (Trial), II (CAMPCS), III (CAMPCS/2), and IV (CAMPCS/3) Completed
  2. Phase 3 Study of Acid Reflux in Asthma Completed
  3. Phase 3 Scleroderma Lung Disease Completed
  4. Phase 2 Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension Completed
  5. Phase 2 Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE) Completed
  6. Phase 2 Transplanting Hepatitis C Lungs Into Negative Lung Recipients Completed
  7. Phase 2 Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis Completed
  8. Phase 2 Daily Vitamin D for Sickle-cell Respiratory Complications Completed
  9. Phase 2 Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Completed
  10. Phase 2 A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease Completed
  11. Phase 1 Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Completed
  12. Phase 1 Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension Completed
  13. Phase 1 Does Pulmonary Rehabilitation Improve Balance in People With Respiratory Disease? Completed
  14. N/A Safety of a Sheath Cryoprobe Bronchoscopic Transbronchial Biopsy Technique Completed
  15. N/A Continuous Positive Airway Pressure to Improve Milder Obstructive Sleep Apnea Completed
  16. N/A Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program Completed
  17. N/A Promoting Smoking Cessation in Lung Cancer Screening Through Proactive Treatment Completed
  18. N/A Facilitating Communication Study Completed
  19. N/A Lung Ultrasonography vs Fiberoptic Bronchoscopy for Aiding Lung Collapse in Patient Using Double Lumen Tube Completed
  20. N/A Asthma Data Innovation Demonstration Project Completed
  21. N/A AirWaze - Easy and Advanced Tools for CBCT Guided Lung Interventions Completed

Showing the 27 most-cited and recently-updated of 27 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Lung diseases: what the trials found

Patient-controlled analgesia (PCA) was evaluated for pain management in lung disease patients, with results showing varied Visual Analogue Scale (VAS) scores and M.D. Anderson Symptom Inventory (MDASI) scores across study groups 1.

Roflumilast did not demonstrate a statistically significant difference in the rate of moderate or severe COPD exacerbations per patient per year (p=0.1634), nor in the rate of exacerbations leading to hospitalization or death (p=0.6354) 3.

Active CPAP was shown to have a statistically significant effect on certain neurocognitive functions, specifically improving E/F Function- SWMT-OMD (p=0.0074), while showing no significant impact on A/P Function (p=0.4538) or L/M Function (p=0.7936) 5.

Ceftolozane/tazobactam was evaluated for mortality and clinical response; the percentage of patients with all-cause mortality at Day 28 was 24.0% and 25.3%, while clinical cure rates were 54.4% and 53.3% 6.

Montelukast was studied in infants, where observed wheezing-free days were recorded as 25.5 and 30.5 7.

Placebo groups showed specific changes in the rate of asthma-free days (11.3; 9.3; 9.3) and height from baseline to end of treatment (22.7; 23.7; 23.8) over a period of 4-6 years 9.

Esomeprazole did not show statistically significant differences in episodes of poor asthma control (p=0.66), peak expiratory flow drops (p=0.35), or urgent care visits (p=0.79) 10.

Recent results — preliminary, needs further review

  • Daily oral vitamin D3, 3,333 IU was investigated for its effect on FEV1/FVC ratios and RV/TLC ratios 11.
  • AirWaze was evaluated in a study of 37 participants 2.

For the clinician treating this condition

  • Roflumilast did not show statistically significant improvements in COPD exacerbation rates or severe outcomes compared to standard measures 3.
  • Active CPAP demonstrated significant improvements in specific neurocognitive functions (E/F Function- SWMT-OMD) but no effect on others 5.
  • Esomeprazole showed no significant impact on asthma control metrics, including peak expiratory flow or urgent care visit frequency 10.

AI synthesis of 9 cited trials, updated Jul 18, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Bangga extracts show antibacterial, anti-inflammatory, antiviral, and antitumor activity in preclinical synthesis
Drug Pipeline Sys. Review
Bangga extracts show antibacterial, anti-inflammatory, antiviral, and antitumor activity in preclinical synthesis Extracts of Aconitum tanguticum Show Potential for Several Conditions
This systematic review synthesizes preclinical evidence on Aconitum tanguticum (Bangga), reporting antibacterial, anti-inflammatory, antivir…
Research into Aconitum tanguticum extracts shows potential antibacterial, antiviral, and anti-inflammatory properties for various inflammato…
Frontiers Sep 13, 2026
AI diagnostic tools show high accuracy but limited real-world validation in systematic review
Oncology Meta-analysis
AI diagnostic tools show high accuracy but limited real-world validation in systematic review Artificial intelligence shows high accuracy in detecting various medical conditions
This systematic review of 24 studies synthesizes evidence on AI and deep learning for disease detection across multiple imaging modalities. …
New analysis of 24 studies shows AI tools can reach over 90% accuracy in spotting everything from lung cancer to skin disorders.
Frontiers Jul 18, 2026